Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism

Basit Öğe Kaydı
dc.authoridSabuncu, Tevfik/0000-0001-6504-5355
dc.authorwosidSabuncu, Tevfik/ABF-5291-2020
dc.contributor.authorSabuncu, T
dc.contributor.authorAksoy, N
dc.contributor.authorArikan, E
dc.contributor.authorUgur, B
dc.contributor.authorTasan, E
dc.contributor.authorHatemi, H
dc.date.accessioned2024-06-12T11:20:05Z
dc.date.available2024-06-12T11:20:05Z
dc.date.issued2001
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe effects of thyroid hormones on various organs and metabolic systems have been the focus of intensive research. In this study we investigated the mechanisms of the changes in some parameters of bone and mineral metabolism before and during treatment off hyper- and hypothyroidism. Our study groups were as follows; 1) Untreated hyperthyroid patients (n = 38), 2) Hyperthyroid patients treated fbr three months (n = 21), 3) Untreated hypothyroid patients (n = 27), 4) Hypothyroid patients treated for three months (n = 20), and 5) Euthyroid control subjects (age, weight, sex and menopausal status matched) (n = 47). As expected, the mean serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), and urinary Ca/creatinine and deoxypyridinoline (D-Pyr)/creatinine levels were higher in group-1 than in the control group. Serum PTH level was lower in group-1 than in group-5. However, after treatment for three months (group-2) we found that the serum and urinary levels of these parameters (except ALP) were not different than in the control group. Group-3 and group-4 did not show any differences in these parameters compared with group-5. Covariance analysis showed that urinary D-Pyr excretion had a positive, independent relationship to the serum free T3 level and age (P < 0.001 and P = 0.02, respectively). These results suggest that both bone formation and resorption markers increase in hyperthyroid patients, and with the treatment, particularly, in the period of first three months the bone resorption markers decrease rapidly, if the treatment is maintained the decrease slows, becoming more gradual. However, bone formation markers like ALP remain high in hyperthyroid patients during the treatment. In the light of this data, it is possible to conclude that osteoblastic activity lasts longer in hyperthyroidism. On the other hand, we demonstrated that these bone formation and resorption markers do not seem to be different in hypothyroid patients, even during the treatment, compared to the euthyroid controls.en_US
dc.identifier.doi10.1081/ERC-100107181
dc.identifier.endpage213en_US
dc.identifier.issn0743-5800
dc.identifier.issue1-2en_US
dc.identifier.pmid11428712en_US
dc.identifier.startpage203en_US
dc.identifier.urihttps://doi.org/10.1081/ERC-100107181
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25461
dc.identifier.volume27en_US
dc.identifier.wosWOS:000170045600019en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMarcel Dekker Incen_US
dc.relation.ispartofEndocrine Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectThyroxine Replacement Therapyen_US
dc.subjectCalcium-Phosphorus Metabolismen_US
dc.subjectPremenopausal Womenen_US
dc.subjectThyroid-Hormonesen_US
dc.subjectSecondary Osteoporosisen_US
dc.subjectPostmenopausal Womenen_US
dc.subjectBody-Compositionen_US
dc.subjectHyperthyroidismen_US
dc.subjectDensityen_US
dc.subjectTurnoveren_US
dc.titleEarly changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu